Porton Biopharma Digital Brochure - page 3

PBL is the sole manufacturer of Erwinase which is indicated for
the treatment of Acute Lymphoblastic Leukaemia (ALL), the most
common form of cancer in children.
The product is produced in our licensed pharmaceutical
manufacturing facilities. Since its first registration in the UK in
1985 Erwinase has to date been registered in 20 countries and
commercialised in up to 80 countries world-wide, including approval
in the USA by the FDA in November 2011 under the name Erwinaze.
Erwinase is an asparaginase enzyme derived from the bacterium
Erwinia chrysanthemi
that is used as part of the treatment protocols
in conjunction with radiotherapy or chemotherapy. Erwinase is used
when patients demonstrate an allergic reaction to asparaginase
enzymes from other sources.
In those aged 14 or younger, more than 90% will survive their
leukaemia for 5 years or more after they are diagnosed*.
*Cancer Research UK
1,2 4,5,6,7,8
Powered by FlippingBook